

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Guanze Medical Information Industry (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock code : 2427)

VOLUNTARY ANNOUNCEMENT (1) GRANT OF AWARDED SHARES PURSUANT TO SHARE AWARD SCHEME AND (2) SHARE PURCHASE IN RELATION TO GRANT OF AWARDED SHARES

This announcement is made by Guanze Medical Information Industry (Holding) Co., Ltd. (the “**Company**”) on a voluntary basis. Reference is made to the announcement of the Company dated 2 December 2023 in relation to the adoption of the Share Award Scheme by the Board on 2 December 2023 (the “**Announcement**”). Unless otherwise specified, capitalized terms shall have the same meanings as ascribed to them in the Announcement.

GRANT OF AWARDED SHARES PURSUANT TO THE SHARE AWARD SCHEME

On 6 January 2024, based on the recommendation of the remuneration committee of the Company, the Board (including all independent non-executive Directors) resolved to grant a total of 6,802,000 Awarded Shares under the Share Award Scheme to 16 Selected Participants, who are employees of the Group (the “**Grant**”). The Awarded Shares were granted pursuant to the Scheme Rules at nil consideration and have been accepted by the Selected Participants in accordance with terms of the Grant. To the best of the Directors’ knowledge, information and belief, having made all reasonable enquiries, none of the Selected Participants is a connected person of the Company.

The 6,802,000 Awarded Shares granted to the Selected Participants represent approximately 0.72% of the issued share capital of the Company as at the date of this announcement. Pursuant to the Scheme Rules, the Awarded Shares are to be satisfied solely by Shares purchased from the open market by the Trustee or the Trust Holdco, and accordingly, the Grant will not result in any dilution on the shareholdings of existing shareholders of the Company.

The details of the Grant are set out as follows:

Grantees:	A total of 16 Selected Participants who are employees of the Group
Number of Shares granted and the restrictions thereto:	A total of 6,802,000 Shares, subject to adjustment as set out in the letter of grant
Market price of the Shares on the last trading day <i>Note (1)</i> before the date of the Grant:	HK\$0.67 ^{Note (2)}
Vesting date of the Awarded Shares:	Subject to lapse conditions pursuant to the Scheme Rules, the Awarded Shares shall vest on 5 January 2029, which is 5 years from the date of the Grant (inclusive)

Notes:

- (1) Trading day of the Stock Exchange.
- (2) Based on the closing price of HK\$0.67 per Share as quoted on the Stock Exchange on 5 January 2024.

The Company shall procure the Trustee or the Trust Holdco to make on-market purchase(s) of existing Shares of the Company to satisfy the Grant upon vesting. The purchase of existing Shares by the Trustee or Trust Holdco shall be financed with funds provided by the Company in accordance with the Scheme Rules.

SHARE PURCHASES IN RELATION TO THE GRANT OF AWARDED SHARES

The Company was informed by the Trustee that the Trustee or the Trust Holdco has made on-market purchases an aggregate of 6,802,000 Shares during the period from 16 January 2024 to 26 January 2024 (the “**Shares Purchased**”) for the purpose of satisfying the Grant. Details of the Shares Purchased are as follows:

Purchase period:	16 January 2024 to 26 January 2024
Settlement date:	18 January 2024 to 30 January 2024
Total number of Shares Purchased:	6,802,000 Shares

Percentage of the Shares Purchased to the total number of issued share capital of the Company as at the date of the announcement: Approximately 0.72%

Total consideration paid for the Purchased Shares: HK\$5,200,760

Average consideration per Share: Approximately HK\$0.76

Balance of number of Shares held by the Trustee or the Trust Holdco immediately after the purchase and at the date of this announcement: 6,802,000 Shares

The 6,802,000 Shares held by the Trustee or the Trust Holdco in relation to the Grant are regarded as being held in public hands under the Listing Rules.

By order of the Board
Guanze Medical Information Industry (Holding) Co., Ltd.
Meng Xianzhen
Chairman of the Board

Hong Kong, 2 February 2024

As at the date of this announcement, the Board comprises Mr. Meng Xianzhen and Mr. Guo Zhenyu as executive directors; Ms. Meng Cathy as non-executive director; and Dr. Zhao Bin, Dr. Chang Shiwang and Dr. Wong Man Hin Raymond as independent non-executive directors.